Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pacific Biosciences (PACB)

Pacific Biosciences (PACB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pacific Biosciences 1305 O`BRIEN DRIVE MENLO PARK CA 94025 USA

P: 650-521-8000

Description:

Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved.

Key Statistics

Overview:

Market Capitalization, $K 1,002,992
Shares Outstanding, K 224,383
Annual Sales, $ 130,510 K
Annual Net Income, $ -181,220 K
Last Quarter Sales, $ 33,170 K
Last Quarter Net Income, $ -81,500 K
60-Month Beta 1.52
% of Insider Shareholders 1.40%
% of Institutional Shareholders 96.72%
Float, K 221,242
% Float 98.60%
Short Volume Ratio 0.62

Growth:

1-Year Return -86.99%
3-Year Return -26.84%
5-Year Return 29.94%
5-Year Revenue Growth 43.88%
5-Year Earnings Growth -12.05%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.37 on 05/04/22
Next Earnings Date 08/02/22
Earnings Per Share ttm -1.11
EPS Growth vs. Prev Qtr -23.33%
EPS Growth vs. Prev Year -105.56%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PACB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -36.11%
Return-on-Assets % -13.12%
Profit Margin % -138.86
Net Margin % -1,179.04
Debt/Equity 1.22
Price/Sales 7.60
Price/Cash Flow N/A
Price/Book 1.35
Book Value/Share 3.27
Interest Coverage -20.94
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar